Ticker >

Torrent Pharma share price

Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM BSE: 500420 SECTOR: Pharmaceuticals & Drugs  76k   235   19

1864.15
-16.10 (-0.86%)
NSE: 04 Oct 03:50 PM

Price Summary

Today's High

₹ 1881.8

Today's Low

₹ 1851.2

52 Week High

₹ 2094.55

52 Week Low

₹ 1445.55

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

63091.31 Cr.

Enterprise Value

67509.26 Cr.

No. of Shares

33.84 Cr.

P/E

60.49

P/B

9.31

Face Value

₹ 5

Div. Yield

1.18 %

Book Value (TTM)

₹  200.3

CASH

147.61 Cr.

DEBT

4565.56 Cr.

Promoter Holding

71.25 %

EPS (TTM)

₹  30.82

Sales Growth

14.13%

ROE

16.43 %

ROCE

18.1%

Profit Growth

6.05 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Torrent Pharmaceuticals Ltd.

Losar Shelcal Molnutor

Index Presence

The company is present in 28 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.13%
3 Year7.65%
5 Year12.64%

Profit Growth

1 Year6.05%
3 Year3.86%
5 Year16.88%

ROE%

1 Year16.43%
3 Year17.62%
5 Year17.39%

ROCE %

1 Year18.1%
3 Year17.11%
5 Year15.9%

Debt/Equity

0.7072

Price to Cash Flow

27.85

Interest Cover Ratio

6.29770223058318

CFO/PAT (5 Yr. Avg.)

1.80695100542283

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2023 71.25 0
Mar 2023 71.25 0
Dec 2022 71.25 0
Sep 2022 71.25 0
Jun 2022 71.25 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 30.7619689403731% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 37.6336200129556 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.80695100542283.
  • The company has a high promoter holding of 71.25%.

 Limitations

  • The company has shown a poor profit growth of 3.85840432996465% for the Past 3 years.
  • The company has shown a poor revenue growth of 7.6502036289704% for the Past 3 years.
  • The company is trading at a high PE of 60.49.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
Net Sales 1933 1928 1857 1920 2121
Total Expenditure 1268 1308 1272 1342 1384
Operating Profit 665 620 585 578 737
Other Income 29 11 15 26 11
Interest 51 62 91 94 90
Depreciation 149 156 156 182 183
Exceptional Items 0 0 0 0 0
Profit Before Tax 494 413 353 328 475
Tax 167 141 124 109 152
Profit After Tax 327 272 229 219 323
Adjusted EPS (Rs) 9.66 8.04 6.77 6.47 9.54

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 5762.48 6168.44 6450.57 6742.32 7695.2
Total Expenditure 4149.45 4251.45 4258.84 4641.6 5230.04
Operating Profit 1613.03 1916.99 2191.73 2100.72 2465.16
Other Income 381.96 236.93 118.34 204.21 81.88
Interest 480.97 430.49 334.12 236.29 297.68
Depreciation 578.9 606.66 609.84 602.43 672.34
Exceptional Items 0 0 0 0 0
Profit Before Tax 935.12 1116.77 1366.11 1466.21 1577.02
Tax 189.7 178.26 228.26 474.76 525.63
Net Profit 745.42 938.51 1137.85 991.45 1051.39
Adjusted EPS (Rs.) 22.02 27.73 33.62 29.29 31.06

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 84.62 84.62 84.62 84.62 169.23
Total Reserves 4930.65 5036.35 5945.48 6260.8 6286.73
Borrowings 3739.99 3139.99 2941.07 1971.6 2331.78
Other N/C liabilities 184.19 168.27 175.74 412.18 675.04
Current liabilities 3087.82 3387.48 2585.8 2423.36 3409.15
Total Liabilities 12027.27 11816.71 11732.71 11152.56 12871.93
Assets
Net Block 7425.15 7197.5 6741.24 6251.25 7971.85
Capital WIP 470.88 513.33 554.84 543.54 674.9
Intangible WIP 26.7 23.08 33.27 23.96 23.03
Investments 134.87 134.87 174.87 183.66 205.12
Loans & Advances 93.35 100.91 75.61 65.3 68.42
Other N/C Assets 127.37 27.76 11 151.45 1.53
Current Assets 3748.95 3819.26 4141.88 3933.4 3927.08
Total Assets 12027.27 11816.71 11732.71 11152.56 12871.93
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 935.12 1116.77 1366.11 1466.21 1577.02
Adjustment 820.78 857.08 884.8 827.91 990.49
Changes in Assets & Liabilities -315.89 -187.25 -468.12 86.25 -29.64
Tax Paid -208.18 -206.7 -209.9 -240.27 -272.46
Operating Cash Flow 1231.83 1579.9 1572.89 2140.1 2265.41
Investing Cash Flow -373.33 269.43 -316.28 -159.7 -2325.75
Financing Cash Flow -927.58 -1555.48 -1581.2 -1977.27 80.74
Net Cash Flow -69.08 293.85 -324.59 3.13 20.4

Corporate Actions

Investors Details

PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
promoters 71.25 71.25 71.25 71.25 71.25
torrent investments priva... 71.25 71.25 71.25 71.25 71.25
PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
investors 28.75 28.75 28.75 28.75 28.75
investor education and pr... - 0.11 0.11 0.11 0.11
kotak mahindra trustee co... - - - - 1.12
icici prudential life ins... 1.40 1.47 1.24 1.25 -
kotak equity hybrid 1.01 1.05 - 1.20 -
mirae asset large cap fun... 2.17 - - 1.53 -
kotak mahindra trustee co... - - 1.21 - -
mirae asset equity saving... - - 1.59 - -
mirae asset nifty next 50... - 1.88 - - -
nippon life india trustee... - 1.01 - - -
iepf 0.11 - - - -
nippon life india trustee... 1.23 - - - -
uti flexi cap fund 1.11 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Torrent Pharmaceuticals informs about issuance of duplicate share certificates15 Sep 2023, 2:31PM Torrent Pharmaceuticals informs about press release24 Aug 2023, 1:01PM Torrent Pharmaceuticals gets EIR for Dahej manufacturing facility24 Aug 2023, 9:44AM Torrent Pharmaceuticals informs about disclosure 24 Aug 2023, 9:28AM Torrent Pharmaceuticals commences commercial operations of Oral Oncology facility at Gujarat8 Aug 2023, 10:58AM Torrent Pharma - Quaterly Results7 Aug 2023, 4:40PM Torrent Pharma - Quaterly Results7 Aug 2023, 4:40PM Torrent Pharma - Quaterly Results7 Aug 2023, 4:40PM Torrent Pharmaceuticals informs about annual report14 Jul 2023, 5:05PM Torrent Pharmaceuticals gets EIR for Gujarat Oral-Oncology manufacturing facility 16 Jun 2023, 11:51AM Torrent Pharmaceuticals informs about conference call transcript3 Jun 2023, 3:32PM Torrent Pharma - Quaterly Results30 May 2023, 4:56PM Torrent Pharma - Quaterly Results30 May 2023, 4:56PM Torrent Pharma - Quaterly Results30 May 2023, 4:56PM Torrent Pharmaceuticals informs about teleconference16 May 2023, 12:20PM Torrent Pharmaceuticals informs about board meeting 16 May 2023, 10:25AM Torrent Pharmaceuticals informs about loss of share certificates 27 Mar 2023, 4:51PM USFDA concludes pre-approval inspection at Torrent Pharmaceuticals’ Gujarat facility20 Mar 2023, 11:50AM Torrent Pharmaceuticals informs about newspaper publication16 Mar 2023, 5:08PM Torrent Pharmaceuticals informs about analyst meet18 Feb 2023, 3:04PM Torrent Pharmaceuticals forays into OTC segment with calcium supplement brand14 Feb 2023, 2:29PM Torrent Pharmaceuticals reports 14% rise in Q3 consolidated net profit27 Jan 2023, 12:50PM Torrent Pharma - Quaterly Results25 Jan 2023, 4:40PM Torrent Pharma - Quaterly Results25 Jan 2023, 4:40PM Torrent Pharma - Quaterly Results25 Jan 2023, 4:40PM Torrent Pharmaceuticals informs about press release14 Dec 2022, 4:27PM Torrent Pharmaceuticals enters into partnership with Boehringer Ingelheim India14 Dec 2022, 4:00PM Torrent Pharmaceuticals informs about investors meet14 Nov 2022, 5:16PM Torrent Pharmaceuticals raises Rs 500 crore through NCDs10 Nov 2022, 11:00AM Torrent Pharmaceuticals informs about credit rating4 Nov 2022, 10:20AM Torrent Pharma - Quaterly Results21 Oct 2022, 5:56PM Torrent Pharma - Quaterly Results21 Oct 2022, 5:56PM Torrent Pharmaceuticals informs about conference call with analyst meet15 Oct 2022, 12:03PM USFDA concludes inspection at Torrent Pharmaceuticals’ Gujarat manufacturing facility 29 Sep 2022, 9:28AM Torrent Pharmaceutical informs about closure of trading window 28 Sep 2022, 12:38PM Torrent Pharmaceuticals informs about acquisition27 Sep 2022, 5:02PM Torrent Pharmaceuticals inks pacts to acquire 100% stake in Curatio27 Sep 2022, 4:25PM ICRA upgrades Torrent Pharma’s long term credit rating to ‘AA+/Stable’26 Aug 2022, 11:19AM Torrent Pharma - Quaterly Results29 Jul 2022, 6:04PM Torrent Pharma - Quaterly Results29 Jul 2022, 6:04PM Torrent Pharmaceuticals informs about clarification 21 Jul 2022, 9:15AM Torrent Pharmaceuticals informs about allotment of equity shares13 Jul 2022, 2:50PM Torrent Pharmaceuticals informs about press release31 May 2022, 3:19PM Torrent Pharma enters into agreement with Dr Reddy's Laboratories27 May 2022, 9:37AM Torrent Pharmaceuticals reports consolidated net loss of Rs 118 crore in Q426 May 2022, 12:05PM Torrent Pharma - Quaterly Results25 May 2022, 5:50PM Torrent Pharma - Quaterly Results25 May 2022, 5:50PM Torrent Pharmaceuticals board to consider bonus issue 23 May 2022, 5:24PM Torrent Pharmaceuticals reports 16% fall in Q3 consolidated net profit27 Jan 2022, 2:18PM Torrent Pharmaceuticals informs about trading window closure29 Dec 2021, 3:44PM

Torrent Pharma Stock Price Analysis and Quick Research Report. Is Torrent Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Torrent Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 2265.41 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Torrent Pharma has a Debt to Equity ratio of 0.7072 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Torrent Pharma , the EPS growth was 6.05162625079802 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Torrent Pharma has OPM of 32.0350348269051 % which is a good sign for profitability.
     
  • ROE: Torrent Pharma have a average ROE of 16.4261978005496 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Last Updated on:
Brief about Torrent Pharma

Torrent Pharmaceuticals Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Torrent Pharmaceuticals Ltd. is a leading Indian pharmaceutical company that has been providing quality healthcare products to its customers for over five decades. In this article, we will provide a comprehensive analysis of Torrent Pharmaceuticals Ltd. stock from a long-term investor's perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Torrent Pharmaceuticals Ltd. Share Price:

Torrent Pharmaceuticals Ltd.'s share price is a key indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s share price and identify any trends or patterns. The company's share price has shown a stable trend over the past few years, reflecting the company's solid financial position and growth prospects.

Torrent Pharmaceuticals Ltd. Balance Sheet:

Torrent Pharmaceuticals Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and other assets, while liabilities include loans, borrowings, and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s balance sheet and identify any red flags. The company's balance sheet has shown a stable trend over the past few years, reflecting the company's solid financial position and growth prospects.

Torrent Pharmaceuticals Ltd. Annual Report:

Torrent Pharmaceuticals Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Torrent Pharmaceuticals Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Torrent Pharmaceuticals Ltd. Dividend:

Torrent Pharmaceuticals Ltd. has a consistent dividend payout history. The company has paid dividends in every year, reflecting its commitment to rewarding shareholders. Long-term investors should consider this when evaluating Torrent Pharmaceuticals Ltd.'s stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Torrent Pharmaceuticals Ltd. Quarterly Results:

Torrent Pharmaceuticals Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Torrent Pharmaceuticals Ltd. Stock Price:

The stock price of Torrent Pharmaceuticals Ltd. is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Torrent Pharmaceuticals Ltd.'s stock price and identify potential buying opportunities. The stock price of Torrent Pharmaceuticals Ltd. has shown a stable trend over the past few years, reflecting the company's solid financial performance and growth prospects.

Torrent Pharmaceuticals Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Torrent Pharmaceuticals Ltd. has shown a stable trend over the past few years, reflecting the company's solid financial performance and growth prospects.

Torrent Pharmaceuticals Ltd. News:

Keeping up to date with the latest news about Torrent Pharmaceuticals Ltd. is important for investors. Our website provides the latest news about Torrent Pharmaceuticals Ltd. from various sources such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Torrent Pharmaceuticals Ltd. Concall:

Torrent Pharmaceuticals Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Torrent Pharmaceuticals Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Torrent Pharmaceuticals Ltd. Transcripts:

Transcripts of Torrent Pharmaceuticals Ltd.'s concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Torrent Pharmaceuticals Ltd. Investor Presentations:

Torrent Pharmaceuticals Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Torrent Pharmaceuticals Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Torrent Pharmaceuticals Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Torrent Pharmaceuticals Ltd.'s promoters include the promoters group and public shareholding. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Torrent Pharmaceuticals Ltd. are relatively stable, which is a positive sign for long-term investors.

Torrent Pharmaceuticals Ltd. Shareholders:

Torrent Pharmaceuticals Ltd. has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Torrent Pharmaceuticals Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Torrent Pharmaceuticals Ltd. is diverse, which is a positive sign for long-term investors.

Torrent Pharmaceuticals Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

X